New Light on the Way Blood Vessels Grow

New research conducted by a group of EU-funded researchers is shedding new light on the way blood vessels grow, overturning years of medical thought. The findings have important implications for the development of novel drugs to treat diseases such as cancer, many of which target the tumour's ability to grow its own blood vessels.

Angiogenesis is the process of growing new blood vessels. It is a normal process in growth and development, and plays a key role in a number of diverse situations including healing wounds and traumas, cardiovascular disorders, inflammatory conditions such as rheumatoid arthritis, and in cancer growth. However, it is also a fundamental step in the transition of tumours from a dormant state to a malignant state.

Current thinking holds that the endothelial cells which line the blood vessel wall have their origins in circulating stem cells which are first mobilised from the bone marrow. These subsequently differentiate to produce mature bona fide endothelial cells which are incorporated into the blood vessels. This concept has become textbook material, and a common theme in modem vascular and cancer biology. Crucially, it was also believed that cancerous tumours also relied on these circulating stem cells to build up their own networks of blood vessels.

However, new research coming out of Europe and the US shows that bone marrow-derived circulating endothelial precursors do not contribute to the vascular endothelium, and they are not needed for tumour growth either. The research was led by Dr Petri Salvén from the University of Helsinki, Finland, and stem cell research pioneer Dr Irving Weissman at Stanford University, California.

Together they succeeded in showing that circulating endothelial precursor cells do not actually exist and that angiogenesis and cancer growth neither involve nor depend on such hypothetical stem cells. They were able to show this by studying angiogenesis in mice using the latest in three dimensional cellular imaging technologies.

The researchers note that both blood vessels and tumour tissues contain large numbers of bone marrow derived cells such as ordinary white blood cells that are often very close to blood vessel walls. They speculate that these may have been misinterpreted as blood vessel wall endothelial cells in earlier studies using less advanced technologies.

The results have great practical significance for researchers who are trying to develop novel cancer treatments designed to target the normal cells of the body which supply tumours with blood and nutrients. "Our results will help the researchers to concentrate their efforts on molecular and cellular targets that actually exist," says Dr Salvén, leader of the Helsinki team.

"It has been a learning experience to try to publish results that demonstrate that a number of fellow researchers have for years been studying nonexistent cells," Dr. Salvén comments. "Issues concerning publication bias and non-accessibility of negative data are really becoming more and more relevant, just as recently seen also in other fields of biomedicine."

Their findings are to be published in the journal of the Proceedings of the National Academy of Sciences of the United States of America. EU support for the work came from the EU-funded 'Tumor-Host Genomics' project, which is financed through the 'Life sciences, genomics and biotechnology for health' Thematic Area of the Sixth Framework Programme (FP6).

For further information, please visit:
http://www.pnas.org/

Copyright ©European Communities, 2008
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

Therapy using dual immune system cells effectively…

A newly developed immunotherapy that simultaneously uses modified immune-fighting cells to home in on and attack two antigens, or foreign substances, on cancer cells was ...

Cleveland Clinic study suggests steroid nasal spra…

A recent Cleveland Clinic study found that patients who regularly use steroid nasal sprays are less likely to develop severe COVID-19-related disease, including a 20 to 2...

How to develop new drugs based on merged datasets

Polymorphs are molecules that have different molecular packing arrangements despite identical chemical compositions. In a recent paper, researchers at GlaxoSmithKline (GS...

New drug combination effective against SARS-CoV-2 …

More countries with greater resources are opening up for a more normal life. But COVID-19 and the SARS-CoV-2 virus are still a significant threat in large parts of the wo...

Sanofi to focus its COVID-19 development efforts o…

Recent positive interim results of Sanofi's mRNA-based COVID-19 vaccine candidate Phase 1/2 study confirm the company's platform robust capabilities and strategy in mRNA...

Discovery of mechanics of drug targets for COVID-1…

A team of international researchers, including McGill Professor Stéphane Laporte, have discovered the working mechanism of potential drug targets for various diseases suc...

Phase II/III trial shows Ronapreve™ (casirivimab a…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed positive data from the phase II/III 2066 study, investigating Ronapreve™ (casirivimab and imdevimab) in patients hospit...

Pfizer and BioNTech receive first U.S. FDA Emergen…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the U.S. Food and Drug Administration (FDA) has authorized for emergency use a booster dose of the P...

AZD7442 request for Emergency Use Authorization fo…

AstraZeneca has submitted a request to the US Food and Drug Administration (FDA) for an Emergency Use Authorization (EUA) for AZD7442, its long-acting antibody (LAAB) com...

Pfizer and BioNTech receive CHMP positive opinion …

Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Committee for Medicinal Products for Human Use (CHMP) of the Europea...

Boehringer Ingelheim acquires Abexxa Biologics to …

Boehringer Ingelheim announced the acquisition of Abexxa Biologics Inc., a biopharmaceutical company taking a new approach in the fields of immuno-oncology and oncology r...

GSK welcomes WHO recommendation for broad roll-out…

GlaxoSmithKline (GSK) plc welcomes and applauds the WHO recommendation for the broader deployment of GSK's RTS,S malaria vaccine to reduce childhood illness and deaths fr...